Bryostatin I in Metastatic Malignant Melanoma
Author Information
Author(s): DJ Propper, V Macaulay, KJ O'Byrne, JP Braybrooke, SM Wilner, TS Ganesan, DC Talbot, AL Harris
Primary Institution: ICRF Medical Oncology Unit, Churchill Hospital, Oxford, UK
Hypothesis
Is bryostatin I effective in treating metastatic malignant melanoma in patients previously treated with chemotherapy?
Conclusion
Single-agent bryostatin appears ineffective in the treatment of metastatic melanoma in patients previously treated with chemotherapy.
Supporting Evidence
- Of 15 evaluable patients, 14 developed progressive disease.
- One patient achieved stable disease for 9 months after treatment.
- The median survival from commencement of bryostatin was 134 days.
Takeaway
The study tested a drug called bryostatin on patients with skin cancer, but it didn't help most of them get better.
Methodology
Patients received bryostatin 25 µg/m² weekly for three courses followed by a rest week, and their responses were evaluated.
Limitations
All patients had previously received chemotherapy, which may have affected the results.
Participant Demographics
16 patients (8 men, 8 women) aged 35-76 years, all with prior chemotherapy.
Statistical Information
Confidence Interval
95% CI = 67-308
Want to read the original?
Access the complete publication on the publisher's website